Sanuwave Health, Inc. · NASDAQ:SNWV

Sanuwave Health — Q3 2024 Earnings Presentation

8 slides from Sanuwave Health's earnings presentation, Nov 8, 2024

  1. Slide 1: Q3 FY2024

    (©) SANUWAVE und Care Technolog’ Q3 FY2024 November 8, 2024

  2. Slide 2: Live Presentation and Dial-in Information

    Live Presentation Friday, November 8, 2024, 8:30 AM (ET) Participant Dial-in Information Toll Free: 1-800-267-6316 Toll/International: 1-203-518-9783 Conference ID: SANUWAVE OR click the link for instant telephone access to the event. https://viavid.webcasts.com/starthere.jsp?ei=1692398&tp_key=e3cff

  3. Slide 3: Forward Looking Statements

    3 Forward Looking Statements This presentation may contain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, such as statements relating to future financial results, production expectations, and plans for future business development activities.

  4. Slide 4: Financials Q3 2024

    4 Financials Q3 2024 Consistent topline growth while managing operating costs. (in millions) Q3 2024 Q3 2023 YoY Revenue $9.4 $5.0 + 89% Gross Profit $7.1 $3.5 + 100% Gross Margin 75.5% 71.5% +401bp Operating Expense $5.1 $4.1 +26% Revenue Gross Profit Operating I n c o m e ( l o s s ) Operating Inc

  5. Slide 5: Improved operational results

    5 Improved operational results See Non-GAAP Financial Measures disclosure included on slide 3

  6. Slide 6: Growing UltraMist Systems & Consumables Sales

    6 Growing UltraMist Systems & Consumables Sales Continuous UltraMIST revenue growth throughout 2023. Strong year on year growth in 2024. $6.0 + 75% yoy • 912 Active Systems* in the +14% seq field at end of Q3 2024 $5.0 +144% yoy • In Q3 2024: 124 systems sold +74% seq $4.0 (vs 55 in Q3 2023 and 72 i

  7. Slide 7: Q4 and FY 2024 Revenue Guidance

    7 Q4 and FY 2024 Revenue Guidance Q4 2024 FY 2024 REVENUE GROWTH REVENUE GROWTH >$32 million +40-50% (+57%) vs vs Q4 2023 REVENUE FY 2023 REVENUE of $6.99 million of $20.4 million

  8. Slide 8: Summary

    8 Summary Wound care is undergoing a payor led shift to evidence based medicine and reimbursement. This has aligned incentives for Patients, Payors, and Providers. SANUWAVE is in a prime position to benefit: ▪ Approved products protected by strong IP ▪ Strong existing reimbursement with room to impr

SANUWAVE Health — Q3 2024 Earnings Presentation on 6ix